# DeLLphi-306 (NCT06117774)

> Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06117774
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer
- Interventions: Tarlatamab; Placebo
- Enrollment: 404
- Primary outcome: PFS as Determined by BICR
- Primary outcome: OS Over the Whole Trial

## Commentary we found

- YouTube: 10
- Podcasts: 7
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=dellphi-306-nct06117774

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06117774", "email": "<work email>"}; the inbox owner confirms by the emailed link.